Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran58 enrolled

Overview

Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal dialysis and 25(OH) vitamin D deficiency.

Patients with chronic kidney disease on peritoneal dialysis have very low 25-(OH) vitamin D levels. Vitamin D deficiency may be involved in generalized atherosclerosis, vascular calcification and cardiovascular mortality. Among others, Osteoprotegerin (OPG) has been implicated in the pathogenesis leading up vessel calcification in this patients. Furthermore, very low levels of 25-(OH) vitamin D in peritoneal dialysis patients are associated with increased levels of OPG and high values of vascular calcification scores in x-rays. It is unknown whether cholecalciferol supplementation in patients on peritoneal dialysis with low levels of 25-(OH) vitamin D could change the proteins associated with vascular calcification. The objective is to conduct a randomized, double-blind, placebo-controlled study focusing on the impact of Cholecalciferol substitution in 25-OH vitamin D deficient peritoneal dialysis patients on circulating OPG and other osteogenic biomarkers levels during 16 weeks of intervention. Moreover, the impact of cholecalciferol on serum calcium and phosphorus levels, Kidney Disease Quality of Life Short Form, and ultrasound characteristics of carotid arterial will be performed during the first four weeks after inclusion, and after 28 weeks postintervention. Peritoneal dialysis patients found to have 25-(OH) vitamin D levels \<20 ng/ml will be included and will be randomized to receive either oral cholecalciferol therapy or placebo. Cholecalciferol will be administered at a daily dose of 4800 IU over a time period of 16 weeks. All in all, 58 subjects will be included in this study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Vitamin D Deficiency Vascular Calcification Renal Insufficiency End Stage Renal Failure on Dialysis

Interventions

CholecalciferolDRUG

Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.

PlaceboDRUG

An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Peritoneal dialysis treatment for at least 3 months. * Concentrations of 25-oh vitamin D \<20 ng / mL * Corrected calcium \<10.5 mg / dL * Serum phosphorus \<7.0 mg / dL * Intact parathyroid hormone \> 50 pg / mL and \<1500 pg/mL Exclusion Criteria: * Active participation in another protocol. * Vitamin D deficiency due to a hereditary disease or liver disease. * Use of cholecalciferol ≥ 2000 IU per day within 6 months prior * New prescription of calcitriol or paricalcitol at any dose within three months prior to the intervention (The subjects may be taking calcitriol or paricalcitol only if these drugs are taken at least three months before and no substantial changes in dosage have been made). * Use of bisphosphonates. * Treatment with anticonvulsants or other drugs that affect the metabolism of vitamin D. * Pregnancy and lactation. * Active cancer or other active inflammatory disease. * HIV or AIDS

Locations (1)

National Medical Science and Nutrition Institute Salvador Zubiran MEXICO

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Relative reduction in serum osteoprotegerin (OPG) levels assessed by ELISA (in pg/mL) between study inclusion, and the 16-week intervention period.

The concentrations of OPG will be assessed using ELISA (Austin, Texas, USA) at inclusion and after 16 weeks of treatment with cholecalciferol or placebo.Minimum detectable concentrations for OPG are 1.9 pg/mL; intra and inter-assay coefficients of variability are 5% and 11% for OPG.

Time frame: 16 weeks

Secondary Outcomes

Relative reduction in circulating intact fibroblast growth factor 23 (FGF23) levels (in pg/mL)

The concentrations of intact FGF-23 will be assessed using ELISA (Austin, Texas, USA)

Time frame: 16 weeks

Relative reduction in circulating osteopontin (OPN) levels (in pg/mL)

The concentrations of OPN will be assessed using ELISA (Austin, Texas, USA)

Time frame: 16 weeks

Relative reduction in circulating osteocalcin (OCN) levels (in pg/mL)

The concentrations of OCN will be assessed using ELISA ( Austin, Texas, USA)

Time frame: 16 weeks

Relative reduction in intima-media thickness measurements in the carotid artery. Ultrasound examination will be performed at study inclusion, at 16 weeks after inclusion, and up to 52 weeks post inclusion.

Ultrasound examination will be performed with the use of an 8-megahertz annular array ultrasound imaging system by a single trained sonographer. With this technique, 2 parallel echogenic lines separated by an anechoic space can be visualized at levels of the artery wall. The distance between the 2 lines gives a reliable index of the thickness of the intimal-medial complex. Subjects will be examined in the supine position. Ultrasound scans of the right and left last distal centimeter of common carotid arteries and bifurcation and of the first proximal centimeter of internal carotid arteries in 3 different projections (anterior, lateral, and posterior) will be performed. All measurements will be made at the time of scanning on unfrozen images of longitudinal scans by using the machine's electronic caliper.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.